DF2755A   Click here for help

GtoPdb Ligand ID: 12230

Synonyms: DF 2755A | DF-2755A
Compound class: Synthetic organic
Comment: DF2755A inhibits CXCL8 (IL-8) signalling via its endogenous chemokine receptors CXCR1 and CXCR2 [2]. It does not alter the binding affinity of CXCL8 for either receptor, indicating that it is behaving as a negative allosteric modulator (NAM). Activation of the IL-8 pathway has been linked to the development of chemotherapy-induced neuropathic pain. It is predicted that inhibition of this mechanism might offer clinical utility for cancer patients who experience chemotherapy-induced peripheral neuropathy [1].
We show the carboxylic acid parent form for this compound, but DF2755A is used as the sodium salt.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 90.46
Molecular weight 316.3
XLogP 2.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H](c1ccc(cc1)Nc1scc(n1)C(F)(F)F)C(=O)O
Isomeric SMILES C[C@H](C(=O)O)c1ccc(Nc2nc(cs2)C(F)(F)F)cc1
InChI InChI=1S/C13H11F3N2O2S/c1-7(11(19)20)8-2-4-9(5-3-8)17-12-18-10(6-21-12)13(14,15)16/h2-7H,1H3,(H,17,18)(H,19,20)/t7-/m0/s1
InChI Key OUGCUPYREMACGK-ZETCQYMHSA-N
No information available.
Summary of Clinical Use Click here for help
An ascending dose tolerability study has been completed in healthy volunteers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04803396 Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A Phase 1 Interventional Dompé Farmaceutici S.p.A